VELA Investment Management LLC Sells 1,599 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

VELA Investment Management LLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 46.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,818 shares of the biopharmaceutical company’s stock after selling 1,599 shares during the quarter. VELA Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Harbor Capital Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 51 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of Alnylam Pharmaceuticals by 4.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock valued at $187,000 after purchasing an additional 53 shares during the period. EP Wealth Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 6.4% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 71 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of Alnylam Pharmaceuticals by 2.0% in the 1st quarter. CIBC Asset Management Inc now owns 4,191 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 84 shares during the period. Finally, Oppenheimer & Co. Inc. grew its position in Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after buying an additional 93 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 0.1 %

ALNY stock traded up $0.12 during midday trading on Tuesday, reaching $147.82. 18,804 shares of the company traded hands, compared to its average volume of 801,962. Alnylam Pharmaceuticals, Inc. has a 52-week low of $143.52 and a 52-week high of $218.88. The business has a 50 day moving average of $153.53 and a 200-day moving average of $167.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.68) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ALNY shares. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $230.00 to $173.00 in a research report on Friday, February 16th. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. Wolfe Research began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. HC Wainwright restated a “buy” rating and set a $395.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.